entertainment -WSS

entertainment

author：explore 2025-08-20 09:42:28 - browse：42912

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： BridgeBio heart drug succeeds in pivotal study

entertainment

focus

WSS

Johnson & Johnson sues to stop Medicare negotiation

Humans aren't the only ones with an imagination. Rats have it too

Bill would allow buprenorphine prescription for addiction via telehealth

Flagship, Pfizer team up in deal worth up to $7 billion

Infant mortality in U.S. rose last year for first time in decades: CDC

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

knowledge

entertainment

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

A look at other Americans who have crossed into North Korea over the years

BioMarin wins approval for gene therapy to treat hemophilia A

Coloradans with cystic fibrosis could lose access to Trikafta

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

15 die by electrocution after transformer explodes in northern India

hotspot

Key Senate panel to consider PBM, drug pricing reform package

All of Us, NIH's precision medicine initiative, gets a big boost

Readout LOUD podcast: ESMO highlights & Roivant's big deal

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Coloradans with cystic fibrosis could lose access to Trikafta

entertainment

focus

hotspot

focus